Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Intervalo de año de publicación
1.
Free Radic Res ; 58(4): 229-248, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38588405

RESUMEN

Selenium-containing compounds have emerged as promising treatment for redox-based and inflammatory diseases. This study aimed to investigate the in vitro and in vivo anti-inflammatory activity of a novel diselenide named as dibenzyl[diselanediyIbis(propane-3-1diyl)] dicarbamate (DD). DD reacted with HOCl (k = 9.2 x 107 M-1s-1), like glutathione (k = 1.2 x 108 M-1s-1), yielding seleninic and selenonic acid derivatives, and it also decreased HOCl formation by activated human neutrophils (IC50=4.6 µM) and purified myeloperoxidase (MPO) (IC50=3.8 µM). However, tyrosine, MPO-I and MPO-II substrates, did not restore HOCl formation in presence of DD. DD inhibited the oxidative burst in dHL-60 cells with no toxicity up to 25 µM for 48h. Next, an intraperitoneal administration of 25, 50, and 75 mg/kg DD decreased total leukocyte, neutrophil chemotaxis, and inflammation markers (MPO activity, lipid peroxidation, albumin exudation, nitrite, TNF-α, IL-1ß, CXCL1/KC, and CXCL2/MIP-2) on a murine model of carrageenan-induced peritonitis. Likewise, 50 mg/kg DD (i.p.) decreased carrageenan-induced paw edema over 5h. Histological and immunohistochemistry analyses of the paw tissue showed decreased neutrophil count, edema area, and MPO, carbonylated, and nitrated protein staining. Furthermore, DD treatment decreased the fMLP-induced chemotaxis of human neutrophils (IC50=3.7 µM) in vitro with no toxicity. Lastly, DD presented no toxicity in a single-dose model using mice (50 mg/kg, i.p.) over 15 days and in Artemia salina bioassay (50 to 2000 µM), corroborating findings from in silico toxicological study. Altogether, these results demonstrate that DD attenuates carrageenan-induced inflammation mainly by reducing neutrophil migration and the resulting damage from MPO-mediated oxidative burst.


Asunto(s)
Carragenina , Inflamación , Infiltración Neutrófila , Animales , Ratones , Humanos , Inflamación/tratamiento farmacológico , Inflamación/inducido químicamente , Infiltración Neutrófila/efectos de los fármacos , Masculino , Neutrófilos/efectos de los fármacos , Neutrófilos/metabolismo , Edema/tratamiento farmacológico , Edema/inducido químicamente , Peroxidasa/metabolismo , Antiinflamatorios/farmacología , Antiinflamatorios/uso terapéutico , Compuestos de Organoselenio/farmacología , Compuestos de Organoselenio/uso terapéutico , Ácido Hipocloroso
2.
Parasitol Int ; 66(2): 47-55, 2017 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-27888011

RESUMEN

Leishmania (Leishmania) infantum chagasi is one of the agents that cause visceral leishmaniasis. This disease occurs more frequently in third world countries, such as Brazil. The treatment is arduous, and is dependent on just a few drugs like the antimonial derivatives and amphotericin B. Moreover, these drugs are not only expensive, but they can also cause severe side effects and require long-term treatment. Therefore, it is very important to find new compounds that are effective against leishmaniasis. In the present work we evaluated a new group of synthetic amides against the promastigote and amastigote forms of L. infantum chagasi. The results showed that one of these amides in particular, presented very effective activity against the promastigotes and amastigotes of L. infantum chagasi at low concentrations and it also presented low toxicity for mammal cells, which makes this synthetic amide a promising drug for combating leishmaniasis.


Asunto(s)
Antiprotozoarios/farmacología , Leishmania infantum/efectos de los fármacos , Fenetilaminas/farmacología , Animales , Antiprotozoarios/síntesis química , Antiprotozoarios/química , Brasil , Línea Celular , Descubrimiento de Drogas , Leishmania/efectos de los fármacos , Leishmania/ultraestructura , Leishmania infantum/crecimiento & desarrollo , Leishmania infantum/fisiología , Leishmania infantum/ultraestructura , Estadios del Ciclo de Vida/efectos de los fármacos , Macrófagos Peritoneales/efectos de los fármacos , Ratones , Fenetilaminas/síntesis química , Fenetilaminas/química
3.
BMC Microbiol ; 14: 201, 2014 Jul 26.
Artículo en Inglés | MEDLINE | ID: mdl-25062749

RESUMEN

BACKGROUND: Resistance to fluconazole, a commonly used azole antifungal, is a challenge for the treatment of fungal infections. Resistance can be mediated by overexpression of ABC transporters, which promote drug efflux that requires ATP hydrolysis. The Pdr5p ABC transporter of Saccharomyces cerevisiae is a well-known model used to study this mechanism of antifungal resistance. The present study investigated the effects of 13 synthetic compounds on Pdr5p. RESULTS: Among the tested compounds, four contained a tellurium-butane group and shared structural similarities that were absent in the other tested compounds: a lateral hydrocarbon chain and an amide group. These four compounds were capable of inhibiting Pdr5p ATPase activity by more than 90%, they demonstrated IC50 values less than 2 µM and had an uncompetitive pattern of Pdr5p ATPase activity inhibition. These organotellurides did not demonstrate cytotoxicity against human erythrocytes or S. cerevisiae mutant strains (a strain that overexpress Pdr5p and a null mutant strain) even in concentrations above 100 µM. When tested at 100 µM, they could reverse the fluconazole resistance expressed by both the S. cerevisiae mutant strain that overexpress Pdr5p and a clinical isolate of Candida albicans. CONCLUSIONS: We have identified four organotellurides that are promising candidates for the reversal of drug resistance mediated by drug efflux pumps. These molecules will act as scaffolds for the development of more efficient and effective efflux pump inhibitors that can be used in combination therapy with available antifungals.


Asunto(s)
Transportadoras de Casetes de Unión a ATP/metabolismo , Antifúngicos/farmacología , Farmacorresistencia Fúngica/efectos de los fármacos , Inhibidores Enzimáticos/metabolismo , Fluconazol/farmacología , Proteínas de Saccharomyces cerevisiae/metabolismo , Saccharomyces cerevisiae/efectos de los fármacos , Telurio/metabolismo , Transportadoras de Casetes de Unión a ATP/genética , Butanos/metabolismo , Butanos/toxicidad , Eritrocitos/efectos de los fármacos , Eritrocitos/fisiología , Concentración 50 Inhibidora , Saccharomyces cerevisiae/genética , Proteínas de Saccharomyces cerevisiae/genética , Telurio/toxicidad
4.
Arq. bras. neurocir ; 18(2): 97-101, jun. 1999. ilus, tab
Artículo en Portugués | LILACS | ID: lil-299410

RESUMEN

Determinados procedimentos cirúrgicos na face, no crânio e na órbita podem desencadear o reflexo trigeminovagal. É feita a revisão sobre fisiopatologia, diagnóstico, tratamento e profilaxia.


Asunto(s)
Humanos , Reflejo Oculocardíaco
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA